Domo signs strategic collaboration agreement with AWS for AI solutions
Michael Feldschuh, the Chief Executive Officer of Daxor Corp (NYSE:NASDAQ:DXR), has recently increased his stake in the company through a notable stock purchase. According to a Form 4 filing with the Securities and Exchange Commission, Feldschuh acquired 3,360 shares of Daxor common stock on March 10, 2025. The shares were purchased at a price of $7.68 each, amounting to a total transaction value of $25,804. The purchase comes as the stock trades near $8, having fluctuated between $6.55 and $10 over the past 52 weeks.
Following this acquisition, Feldschuh’s direct ownership in Daxor has risen to 210,852 shares. This move reflects a continued confidence in the company’s future prospects by its top executive. Daxor Corp, headquartered in New York, is known for its innovative work in blood volume measurement technology, which has applications in various medical fields. InvestingPro data shows the company maintains profitability with a 100% gross margin, though analysts anticipate a sales decline in the current year.
Investors and market watchers often view insider transactions as a potential indicator of a company’s performance outlook. While insider purchases can be seen as a signal of confidence, it’s important for investors to consider a range of factors when evaluating such transactions. Notably, InvestingPro analysis reveals that DXR’s stock price often moves independently of the market, with a beta of -0.53, offering potential diversification benefits. For deeper insights into insider trading patterns and comprehensive analysis, investors can access the full DXR Pro Research Report, available with an InvestingPro subscription.
In other recent news, Daxor Corporation reported an impressive 116.5% increase in revenue for the fourth quarter of 2024, marking a significant year-over-year growth. The company also achieved cash flow breakeven in the first quarter of 2025, demonstrating financial stability. This growth is attributed to innovative product developments and strategic market expansion. Daxor plans to resubmit its next-generation blood volume analyzer for FDA approval, aiming for a 510(k) clearance, and expects significant market interest upon its release. The company has expanded its market presence by signing new accounts and increasing kit sales, which contributed to the revenue surge. In addition, Daxor has entered into agreements to acquire new diagnostic radiopharmaceuticals, which are expected to be immediately cash flow positive. The company’s transition from a 1940 Act to a 1934 Act company designation is anticipated to enhance its market positioning. These developments reflect Daxor’s ongoing efforts to strengthen its financial and operational performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.